ATRA Key Statistics, Chart & Performance
The current stock price of ATRA is 12.22 USD. In the past month the price decreased by -11.77%. In the past year, price decreased by -6.22%.
ATRA Latest News, Press Relases and Analysis
ATRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ATRA
Company Profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 38 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Company Info
ATARA BIOTHERAPEUTICS INC
1280 Rancho Conejo Blvd
Thousand Oaks CALIFORNIA 94080 US
CEO: Pascal Touchon
Employees: 38
Phone: 18056234211
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
Can you describe the business of ATARA BIOTHERAPEUTICS INC?
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 38 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
What is the current price of ATRA stock?
The current stock price of ATRA is 12.22 USD. The price decreased by -9.75% in the last trading session.
Does ATARA BIOTHERAPEUTICS INC pay dividends?
ATRA does not pay a dividend.
What is the ChartMill rating of ATARA BIOTHERAPEUTICS INC stock?
ATRA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is ATARA BIOTHERAPEUTICS INC (ATRA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATRA.
What is the expected growth for ATRA stock?
The Revenue of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 3.31% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ATRA stock?
ATARA BIOTHERAPEUTICS INC (ATRA) has a market capitalization of 88.11M USD. This makes ATRA a Micro Cap stock.
ATRA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ATRA. When comparing the yearly performance of all stocks, ATRA is a bad performer in the overall market: 68.68% of all stocks are doing better.
ATRA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATRA. There are concerns on the financial health of ATRA while its profitability can be described as average.
ATRA Financial Highlights
Over the last trailing twelve months ATRA reported a non-GAAP Earnings per Share(EPS) of 2.18. The EPS increased by 108.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.4% | ||
| ROA | 77.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATRA Forecast & Estimates
9 analysts have analysed ATRA and the average price target is 16.83 USD. This implies a price increase of 37.73% is expected in the next year compared to the current price of 12.22.
For the next year, analysts expect an EPS growth of 112.23% and a revenue growth 3.31% for ATRA